Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™

Clinical trial NCT03263026 · COMPLETED

Trial details

NCT number: NCT03263026
Sponsor: Denovo Biopharma LLC
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Diffuse Large B-Cell Lymphoma

Start date: 2018-03-20
Primary completion: 2022-08-11
Enrollment: 256

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.